Announcements
- NeuroStar® Launches Better Me Provider Program Nationwide
- NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting
- Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents
- NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
- New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
- NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
- Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network
- Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System
- NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update
- Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement Accessory
More ▼
Key statistics
As of last trade Neuronetics Inc (NRC:DUS) traded at 1.59, 1.79% above its 52-week low of 1.56, set on Jun 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.59 |
---|---|
High | 1.59 |
Low | 1.59 |
Bid | 1.64 |
Offer | 1.70 |
Previous close | 1.59 |
Average volume | 0.00 |
---|---|
Shares outstanding | 30.00m |
Free float | 28.00m |
P/E (TTM) | -- |
Market cap | 53.40m USD |
EPS (TTM) | -0.9484 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 07:13 BST.
More ▼